Shots: The P-IIIb/IV PROPEL study involves assessing of Adynovate in prophylaxis targeting two different FVIII trough levels (1–3% REF/ 8–12% ELE) in prior treated patients with severe hemophilia A The […]readmore
Tags : P-IIIB/IV
Shots: The P-IIIb/IV SPIRIT-H2H study results involve assessing of Taltz vs Humira (adalimumab) in 566 patients with PsA who are biologic DMARD-naive for 52wks. The P-IIIb/IV SPIRIT-H2H study results: met […]readmore
Shots: The P-IIIB/IV study results involve assessing of Xeljanz XR (11 mg, qd) as monothx. followed by MTX withdrawal vs Xeljanz XR + MTX in 530 patients in ratio (1:1) […]readmore